2. Search Result
Search Result
Results for "

Flt-3

" in MedChemExpress (MCE) Product Catalog:

353

Inhibitors & Agonists

1

Screening Libraries

1

Fluorescent Dye

1

Biochemical Assay Reagents

2

Peptides

6

Inhibitory Antibodies

3

Natural
Products

25

Recombinant Proteins

14

Isotope-Labeled Compounds

2

Antibodies

5

Oligonucleotides

1

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-130247
    Flonoltinib
    1 Publications Verification

    JAK2/Flt3-IN-1

    		 JAK FLT3 Apoptosis Cancer
    Flonoltinib is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. Flonoltinib has anti-cancer activity .
    Flonoltinib
  • HY-114323
    PROTAC FLT-3 degrader 1

    		PROTACs FLT3 Apoptosis STAT MEK ERK Cancer
    PROTAC FLT-3 degrader 1 is an effective and selective FLT-3 PROTAC degrader with an IC50 of 0.6 nM. PROTAC FLT-3 degrader 1 inhibits both FLT-3 and FLT-3 ITD mutants. PROTAC FLT-3 degrader 1 has the activity of anti-proliferation and induction of apoptosis, which can be used in the study of tumor. (Pink: FLT3 ligand (HY-168702); Black: Linker (HY-124380); Blue: VHL ligand (HY-125845)) .
    PROTAC FLT-3 degrader 1
  • HY-12960
    SKLB4771

    Flt3-​IN-​1

    		 FLT3 c-Kit Apoptosis Cancer
    SKLB4771 is a potent and selective Flt3 inhibitor with an IC50 value of 10 nM. SKLB4771 downregulates the phosphorylation of FLT3/STAT5/ERK, blocks cell proliferation, and induces apoptosis in tumor tissue .
    SKLB4771
  • HY-18161
    CCT241736

    		FLT3 Aurora Kinase Cancer
    CCT241736 is a potent and orally bioavailable dual FLT3 and Aurora kinase inhibitor, which inhibits Aurora kinases (Aurora-A Kd, 7.5 nM, IC50, 38 nM; Aurora-B Kd, 48 nM), FLT3 kinase (Kd, 6.2 nM), and FLT3 mutants including FLT3-ITD (Kd, 38 nM) and FLT3(D835Y) (Kd, 14 nM).
    CCT241736
  • HY-112145
    FLT3-IN-3
    3 Publications Verification

    		 FLT3 Cancer
    FLT3-IN-3 is a potent FLT3 inhibitor with IC50s of 13 and 8 nM for FLT3 WT and FLT3 D835Y, respectively.
    FLT3-IN-3
  • HY-148070
    FLT3-IN-17

    		FLT3 FAK Cytochrome P450 Cancer
    FLT3-IN-17 inhibits CYPs and FLT3 mutants activity (IC50s: <0.5 nM for D835Y). FLT3-IN-17 is also a FAK inhibitor, with an IC50 value of 12 nM. FLT3 ligand-2 can be used in the research of cancers .
    FLT3-IN-17
  • HY-128572
    FLT3-IN-6

    		FLT3 Cancer
    FLT3-IN-6 is a potent and selective inhibitor of FLT3-ITD (FLT3 mutation) with an IC50 of 1.336 nM .
    FLT3-IN-6
  • HY-P990786
    Anti-FLT3 Antibody (AGS62P)

    		FLT3 ADC Antibody Cancer
    Anti-FLT3 Antibody (AGS62P) is an ADC antibody targeting FLT3, and can be used for acute myelogenous leukemia .
    Anti-FLT3 Antibody (AGS62P)
  • HY-159953
    IRAK1/4/pan-FLT3 Kinase-IN-1

    		IRAK FLT3 Cancer
    IRAK1/4/pan-FLT3 Kinase-IN-1 (Compound 31) is a potent inhibitor of IRAK1, IRAK4, and FLT3 kinases, with an IC50 of 5 nM for IRAK1, 0.6 nM for IRAK4, and less than 0.5 nM for FLT3. IRAK1/4/pan-FLT3 Kinase-IN-1 has good pharmacokinetic properties and shows promising potential for research in acute myeloid leukemia, with a survival prolongation effect comparable to that of Gilteritinib (HY-12432) .
    IRAK1/4/pan-FLT3 Kinase-IN-1
  • HY-112475
    Flt-3 Inhibitor III

    		Tie FLT3 Cancer
    Flt-3 Inhibitor III is a potent and selective FLT3 kinase inhibitor with an 50 of 50 nM. Flt-3 Inhibitor III shows less active against other kinases. Flt-3 Inhibitor III has anticancer effects .
    Flt-3 Inhibitor III
  • HY-155195
    FLT3/CHK1-IN-1

    		FLT3 Cancer
    FLT3/CHK-IN-1 (Compound 18) is a dual inhibitor of FLT3/CHK1. FLT3/CHK-IN-1 is more than 1700 times more selective to c-KI T and greatly reduces hERG affinity with an IC50 value of 58.4 μM. FLT3/CHK-IN-1 inhibits tumor growth in mouse xenotransplantation models inoculated with MV-4-11 cells .
    FLT3/CHK1-IN-1
  • HY-175040
    PROTAC FLT-3 degrader 5

    		PROTACs Molecular Glues FLT3 IKZF Family Cancer
    PROTAC FLT-3 degrader 5 is a FLT3 PROTAC degrader (DC50 = 1.2 nM). PROTAC FLT-3 degrader 5 functions as a molecular glue to degrade cereblon substrates GSPT1 and IKZF1/3. PROTAC FLT-3 degrader 5 exhibits antiproliferative activity against drug-resistant acute myeloid leukemia (AML) cells and is potentially useful in AML research. (Pink: FLT3/GSPT1/IKZF1/3 ligand: (HY-169374); Blue: Thalidomide: (HY-14658); Black: linker; Thalidomide + linker: (HY-W1123823)) .
    PROTAC FLT-3 degrader 5
  • HY-130247A
    Flonoltinib TFA
    1 Publications Verification

    JAK2/Flt3-IN-1 TFA

    		 JAK FLT3 Apoptosis Cancer
    Flonoltinib TFA is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. Flonoltinib TFA has anti-cancer activity .
    Flonoltinib TFA
  • HY-P991208
    Flt-3L-Ig (hum/hum)

    human Flt3L; hFlt3L

    		 FLT3 Interleukin Related CCR Inflammation/Immunology
    Flt-3L-Ig (hum/hum) (hFlt3L) is a Flt3 ligand. Flt-3L-Ig (hum/hum) enhances the release of inflammatory cytokines from myeloid cells and dendritic cells in BRGSF-CBC mice induced by OKT3. Flt-3L-Ig (hum/hum) increases the release of IL-2, CCL2 and CXCL10 in an OKT3-dependent manner. Flt-3L-Ig (hum/hum) can be used in studies related to cytokine release syndrome. Flt-3L-Ig (hum/hum) can be used in studies related to psoriasis-like skin inflammation .
    Flt-3L-Ig (hum/hum)
  • HY-158325
    PROTAC FLT-3 degrader 4

    		PROTACs FLT3 Apoptosis Cancer
    PROTAC FLT-3 degrader 4 is an orally active CRBN-based FLT3-PROTAC degrader that potently induces FLT3-ITD degradation through the ubiquitin-proteasome system. PROTAC FLT-3 degrader 4 shows highly selective to FLT3-ITD mutant acute myeloid leukemia (AML) cells. (Blue: CRBN ligand, Black: linker; Pink: FLT3 inhibitor) .
    PROTAC FLT-3 degrader 4
  • HY-178908
    FLT3-IN-35

    		FLT3 Apoptosis Cancer
    FLT3-IN-35 (Compound 4K) is an orally active, covalent, irreversible FLT3 inhibitor. FLT3-IN-35 inhibits the phosphorylation of FLT3 and its downstream signaling factors, as well as induces cell cycle arrest and apoptosis. FLT3-IN-35 inhibits the phosphorylation of FLT3 and its downstream signaling factors, as well as induced cell cycle arrest and apoptosis. FLT3-IN-35 can be used for the study of acute myeloid leukemia (AML) .
    FLT3-IN-35
  • HY-153473
    FLT3-IN-19

    		FLT3 Cancer
    FLT3-IN-19 (Comp 50) is a potent and selective FLT3 inhibitor with IC50 of 0.213 nM. FLT3-IN-19 can be used in AML disease research .
    FLT3-IN-19
  • HY-148521
    PROTAC FLT3/CDK9 degrader-1

    		CDK FLT3 PROTACs Apoptosis Cancer
    PROTAC FLT3/CDK9 degrader-1 is a potent FLT3 and CDK9 dual PROTAC degrader. PROTAC FLT3/CDK9 degrader-1 induces apoptosis and effective degradation of target proteins FLT3 and CDK9. PROTAC FLT3/CDK9 degrader-1 has the potential for the research of FLT3-ITD mutated AML .
    PROTAC FLT3/CDK9 degrader-1
  • HY-128571
    FLT3-IN-4

    		FLT3 Cancer
    FLT3-IN-4 is a potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3; IC50=7 nM) inhibitor for treating acute myelogenous leukemia .
    FLT3-IN-4
  • HY-178858
    PROTAC FLT3/CHK1 Degrader-1

    		PROTACs FLT3 Checkpoint Kinase (Chk) STAT ERK c-Myc Akt Cancer
    PROTAC FLT3/CHK1 Degrader-1 is a PROTAC FLT3/CHK1 degrader, with DC50 values of 5.88 nM (FLT3) and 4.17 nM (CHK1), respectively. PROTAC FLT3/CHK1 Degrader-1 can inhibit the phosphorylation of FLT3 downstream signaling effectors STAT5 (Tyr694), AKT (Ser473), and ERK (Tyr204), downregulate the protein level of c-Myc and maintain the expression of p53 protein. PROTAC FLT3/CHK1 Degrader-1 induces apoptosis in MV-4-11 cells. PROTAC FLT3/CHK1 Degrader-1 shows significant anti-tumor efficacy in mice bearing MV-4-11 subcutaneous xenografts. PROTAC FLT3/CHK1 Degrader-1 can be used for the study of acute myeloid leukemia (AML). (Pink: FLT3/CHK1 ligand (HY-178869 ), Blue: CRBN Ligand (HY-W093272), Black: Linker, E3 ligase ligand-linker conjugate (HY-W998238)) .
    PROTAC FLT3/CHK1 Degrader-1
  • HY-131230
    Desmorpholinyl Quizartinib-PEG2-COOH

    		Target Protein Ligand-Linker Conjugates Cancer
    Desmorpholinyl Quizartinib-PEG2-COOH incorporates a ligand for FLT-3, and a PEG-based PROTAC linker. Desmorpholinyl Quizartinib-PEG2-COOH can be used in the synthesis of PROTAC FLT-3 degrader 1 (HY-114323). PROTAC FLT-3 degrader 1 is a PROTAC FLT-3 internal tandem duplication (ITD) degrader with an IC50 0.6 nM .
    Desmorpholinyl Quizartinib-PEG2-COOH
  • HY-170769
    FLT3 Ligand-Linker Conjugate 1

    		Target Protein Ligand-Linker Conjugates FLT3 Cancer
    FLT3 Ligand-Linker Conjugate 1 (compound 7) contains the FLT3 ligand and a PROTAC linker, which can recruit the E3 ligase VHL. FLT3 Ligand-Linker Conjugate 1 can be used to synthesize the PROTAC RSS0680 (HY-148062). PROTAC RSS0680 is a bifunctional compound that targets protein degradation of kinases .
    FLT3 Ligand-Linker Conjugate 1
  • HY-178444
    Flt-3-IN-1

    		FLT3 Apoptosis Cancer
    Flt-3-IN-1 is a potent FLT-3 inhibitor with an IC50 of 0.91 μM. Flt-3-IN-1 can cause leukemia cells G1 phase arrest and induce apoptosis. Flt-3-IN-1 can be used for the research of cancer, such as leukemia .
    Flt-3-IN-1
  • HY-174437
    FLT3-IN-32

    		FLT3 Apoptosis Cancer
    FLT3-IN-32 is a potent and orally active FLT3 inhibitor. FLT3-IN-32 shows high selectivity for FLT3 and efficiently inhibits FLT3-activating mutations and induces apoptosis. FLT3-IN-32 shows good tolerability in non-tumor bearing mice. FLT3-IN-32 demonstrates outstanding anti-tumor efficacy in MV4-11 bearing NOD/SCID mice, prolonging the survival noticeably. FLT3-IN-32 can be used for the research of acute myeloid leukemia .
    FLT3-IN-32
  • HY-178996
    FLT3-IN-36

    		FLT3 Apoptosis Akt ERK PI3K STAT Mitochondrial Metabolism Cancer
    FLT3-IN-36 is a potent FLT3 inhibitor. FLT3-IN-36 exhibits antitumor activity against FLT3-mutated acute myeloid leukemia (AML) cells. FLT3-IN-36 induces cell cycle arrest, reduces mitochondrial membrane potential, and induces apoptosis, downregulating FLT3 and downstream protein expression (including AKT, ERK, PI3K, and STAT5). FLT3-IN-36 can be used for AML research .
    FLT3-IN-36
  • HY-134481
    FLT3-IN-10

    		FLT3 Cancer
    FLT3-IN-10 (compound 7c) is a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3). FLT3-IN-10 has the potential for the research of FLT3-mutated acute myeloid leukemia (AML) .
    FLT3-IN-10
  • HY-174911
    FLT3-IN-33

    		FLT3 Apoptosis Cancer
    FLT3-IN-33 (Compound 7r) is a FLT3 inhibitor with an IC50 of 7.82  nM. FLT3-IN-33 has superior anticancer activities against acute myeloid leukemia (AML) cells, such as MV4-11 and MOLM-13 cells. FLT3-IN-33 significantly induces cell apoptosis and inhibits phosphorylation of FLT3 pathways. FLT3-IN-33 can be used for AML and other cancers research .
    FLT3-IN-33
  • HY-168702
    FLT3 ligand-2

    		Ligands for Target Protein for PROTAC Cancer
    FLT3 ligand-2 is a Ligand for Target Protein for PROTAC. FLT3 ligand-2 can be used to synthesize PROTAC FLT-3 degrader 1 (HY-114323) .
    FLT3 ligand-2
  • HY-18744
    FLT3-IN-2

    		FLT3 Cardiovascular Disease Cancer
    FLT3-IN-2 (Compound P-0266) is a FLT3 inhibitor with an IC50 of < 1 μM. FLT3-IN-2 can be used in acute myeloid leukemia research .
    FLT3-IN-2
  • HY-178869
    FLT3/CHK1 ligand-1

    		Ligands for Target Protein for PROTAC FLT3 Checkpoint Kinase (Chk) Cancer
    FLT3/CHK1 ligand-1 is a PROTAC target protein ligand that can be used for synthesis of PROTACs, such as PROTAC FLT3/CHK1 Degrader-1 (HY-178858). PROTAC FLT3/CHK1 Degrader-1 is a potent FLT3/CHK1 PROTAC degrader with anti-tumor activity .
    FLT3/CHK1 ligand-1
  • HY-176735
    FLT3/IRAK4-IN-1

    		IRAK FLT3 Apoptosis Cancer
    FLT3/IRAK4-IN-1 is a selective FLT3/IRAK4 inhibitor with the remarkable activity towards FLT3-WT (IC50 = 1.95 nM), FLT3-D835Y (IC50 = 3.22 nM) and IRAK4 (IC50 = 53.72 nM). LT3/IRAK4-IN-1 has relatively low toxicity to normal bone marrow cells, can effectively promote cell apoptosis, and has the potential to overcome drug resistance. FLT3/IRAK4-IN-1 can be used for research on acute myeloid leukemia (AML) .
    FLT3/IRAK4-IN-1
  • HY-161280
    PROTAC FLT-3 degrader 3

    		PROTACs FLT3 Cancer
    PROTAC FLT-3 degrader 3 (compound 35) is a PROTACs degrader of FLT. PROTAC FLT-3 degrader 3 has antiproliferative activity, with IC50 of 7.55 nM in MV4-11 cells .
    PROTAC FLT-3 degrader 3
  • HY-161708
    PROTAC FLT3/CDKs degrader-1

    		PROTACs CDK FLT3 Cancer
    PROTAC FLT3/CDKs degrader-1 (Compound C3) is a degrader for cyclin-dependent kinases (DC50 is 18.73 nM for CDK2) and the FMS-like tyrosine kinase 3 (FLT3). PROTAC FLT3/CDKs degrader-1 induces differentation of HL-60 (72.77% differentation at 6.25 nM), inhibits proliferation of AML cells, with IC50s of 2.9-37 nM. PROTAC FLT3/CDKs degrader-1 is potential for ameliorating acute myeloid leukemia. (Pink: ligand for target protein FLT3/CDKs ligand-1 (HY-161709); Black: linker (HY-W012935); Black: ligand for E3 ligase Thalidomide 5-fluoride (HY-W087383))
    PROTAC FLT3/CDKs degrader-1
  • HY-130247B
    Flonoltinib monomaleate

    JAK2/Flt3-IN-1 monomaleate

    		 JAK FLT3 Apoptosis Cancer
    Flonoltinib maleate is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 has anti-cancer activity .
    Flonoltinib monomaleate
  • HY-RS04991
    Flt3 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Flt3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Flt3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Flt3 Mouse Pre-designed siRNA Set A
    Flt3 Mouse Pre-designed siRNA Set A
  • HY-175610
    PROTAC FLT3/JAK2/BRD4 Degrader-1

    		PROTACs FLT3 JAK Epigenetic Reader Domain Cancer
    PROTAC FLT3/JAK2/BRD4 Degrader-1 is a PROTAC degrader that target FLT3, JAK2, and BRD4 with DC50 values of 5.23, 0.678, and 1.17 nM, respectively. PROTAC FLT3/JAK2/BRD4 Degrader-1 exhibits potent antiproliferative activity against MV4;11 cells (IC50 = 0.79 nM) and FLT3 mutant-transformed Ba/F3 cells. PROTAC FLT3/JAK2/BRD4 Degrader-1 induces apoptosis in MV4;11 cells. PROTAC FLT3/JAK2/BRD4 Degrader-1 demonstrates significant anti-tumor efficacy in the MV4;11 xenograft model established in NOD SCID mice. PROTAC FLT3/JAK2/BRD4 Degrader-1 can be used for the study of acute myeloid leukemia (AML). (Pink: FLT3/JAK2/BRD4 ligand (HY-175611), Blue: CRBN Ligand (HY-W087383), Black: Linker, E3 ligase ligand-linker conjugate (HY-W897939)) .
    PROTAC FLT3/JAK2/BRD4 Degrader-1
  • HY-145904
    PDGFRα/FLT3-ITD-IN-3

    		PDGFR FLT3 Cancer
    PDGFRα/FLT3-ITD-IN-3 (Compound 18d) is a potent inhibitor of PDGFRα/FLT3 with IC50s of 0.153 and 0.004 μM, respectively. PDGFRα/FLT3-ITD-IN-3 has the potential for the research of acute myeloid leukemia or chronic eosinophilic leukemia .
    PDGFRα/FLT3-ITD-IN-3
  • HY-145903
    PDGFRα/FLT3-ITD-IN-2

    		PDGFR FLT3 Cancer
    PDGFRα/FLT3-ITD-IN-2 (Compound 13d) is a potent inhibitor of PDGFRα/FLT3 with IC50s of more than 20 and 1.654 μM, respectively. PDGFRα/FLT3-ITD-IN-2 has the potential for the research of acute myeloid leukemia or chronic eosinophilic leukemia .
    PDGFRα/FLT3-ITD-IN-2
  • HY-145902
    PDGFRα/FLT3-ITD-IN-1

    		PDGFR FLT3 Cancer
    PDGFRα/FLT3-ITD-IN-1 (Compound 12d) is a potent inhibitor of PDGFRα/FLT3 with IC50s of more than 0.036 and 0.003 μM, respectively. PDGFRα/FLT3-ITD-IN-1 has the potential for the research of acute myeloid leukemia or chronic eosinophilic leukemia .
    PDGFRα/FLT3-ITD-IN-1
  • HY-107144
    LY2457546

    		Tyrosinase Ephrin Receptor VEGFR PDGFR FLT3 Tie Cancer
    LY2457546 is a potent and orally active multi-targeted anti-angiogenic tyrosine kinases inhibitor. LY2457546 demonstrates potent activity against targets that include VEGFR2, PDGFRβ, FLT-3, Tie-2 and members of the Eph family of receptors. LY2457546 can be used for the research of cancer, such as leukemia .
    LY2457546
  • HY-E70724
    FLT3 ITD Recombinant Human Active Protein Kinase

    		FLT3 Cancer
    FLT3 (FMS-like tyrosine kinase 3, CD135) is a type 3 receptor tyrosine kinase that plays important roles in cell survival, proliferation, and differentiation during normal hematopoiesis. FLT3 is one of the most frequently mutated genes in acute myeloid leukemia (AML). FLT3 ITD is a internal tandem duplication (ITD) mutation of FLT3 that may be present in AML cells. FLT3 ITD Recombinant Human Active Protein Kinase is a recombinant FLT3 ITD protein that can be used to study FLT3 ITD-related functions .
    FLT3 ITD Recombinant Human Active Protein Kinase
  • HY-115443
    MZH29

    		FLT3 Cancer
    MZH29 is a potent and orally active FLT3 inhibitor. MZH29 shows inhibitory effects on wild-type and mutant FLT3, including the FLT3-ITD, FLT3-D835H/Y/V and FLT3-K663Q mutants. MZH29 retains its potent inhibitory effect against the FLT3-ITD/F691L mutation, a drug resistance mutation against the well-known FLT3 inhibitor, AC220 (HY-13001). MZH29 can be used for the research of cancer, such as acute myeloid leukemia (AML) .
    MZH29
  • HY-RS04992
    Flt3 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Flt3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Flt3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Flt3 Rat Pre-designed siRNA Set A
    Flt3 Rat Pre-designed siRNA Set A
  • HY-RS04990
    FLT3 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    FLT3 Human Pre-designed siRNA Set A contains three designed siRNAs for FLT3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    FLT3 Human Pre-designed siRNA Set A
    FLT3 Human Pre-designed siRNA Set A
  • HY-E70723
    FLT3 D835Y Recombinant Human Active Protein Kinase

    		FLT3 Cancer
    FLT3 (FMS-like tyrosine kinase 3, CD135) is a type 3 receptor tyrosine kinase that plays important roles in cell survival, proliferation, and differentiation during normal hematopoiesis. FLT3 is one of the most frequently mutated genes in acute myeloid leukemia (AML). FLT3 D835Y is the most frequent kinase domain mutation, converting aspartic acid to tyrosine. FLT3 D835Y Recombinant Human Active Protein Kinase is a recombinant FLT3 D835Y protein that can be used to study FLT3 D835Y-related functions .
    FLT3 D835Y Recombinant Human Active Protein Kinase
  • HY-174137
    FLT3-IN-31

    		Apoptosis FLT3 Cancer
    FLT3-IN-31 (compound 10q) is a potent FLT3 inhibitor with IC50 values of 0.16, 2.4 nM for FLT3, FLT3-D835Y, resprctively. FLT3-IN-31 shows antiproliferation activity. FLT3-IN-31 decreases the protein expression of p-FLT3, P-STAT5, P-ERK. FLT3-IN-31 induces apoptosis and cell cycle arrest at G1 phase. FLT3-IN-31 shows antitumor activity .
    FLT3-IN-31
  • HY-112366
    FLT3-IN-38

    		FLT3 Haspin Kinase Cancer
    FLT3-IN-38 (Flt-3 Inhibitor II) is a FLT3 inhibitor. FLT3-IN-38 has off-target effects and inhibits serine/threonine kinase haspin. Haspin is a mitotic signal coordinator. FLT3-IN-38 can be used for cancer research .
    FLT3-IN-38
  • HY-144777
    FLT3-IN-14

    		FLT3 Apoptosis Cancer
    FLT3-IN-14 is a potent FLT3 inhibitor with IC50s of 5.6 nM and 1.4 nM for FLT3-WT and FLT3-ITD. FLT3-IN-14 reduces the phosphorylation of FLT3 (Y591), induces cell cycle arrest at G1 phase and apoptosis. FLT3-IN-14 significantly reduces the tumor growth in an MV4-11 xenograft mouse model .
    FLT3-IN-14
  • HY-162032
    FLT3-IN-25

    		FLT3 Cancer
    FLT3-IN-25 (compound 17) is a potent inhibitor of FLT3, with IC50s of 1.2 nM, 1.4 nM and 1.1 nM for FLT3-WT, FLT3-D835Y and FLT3-ITD, respectively. FLT3-IN-25 plays an important role in acute myeloid leukemia (AML) .
    FLT3-IN-25
  • HY-148522
    FLT3-IN-18

    		FLT3 Cancer
    FLT3-IN-18 is a potent and selective FLT3 inhibitor with an IC50 value of 0.003 μM. FLT3-IN-18 induces apoptosis and cell cycle arrest at G1 phase. FLT3-IN-18 inhibits FLT3 and STAT5 phosphorylation. FLT3-IN-18 has the potential for the research of acute myeloid leukemia (AML) .
    FLT3-IN-18

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: